A series of label expansions for Sanofi and Regeneron’s Dupixent, including its key 2024 FDA
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Regeneron & Sanofi discuss expanding partnership, potentially including Dupixent follow-ons. CEOs Schleifer & Garijo cite need to…
Biopharma sales trended upward in the first quarter of this year as eight of the industry’s top-25 companies achieved…
With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California…
Modern drug development demands faster, more scalable gene expression insights. Download this white paper to explore how…
Antibody-drug conjugates from Kelun-Biotech and Hansoh Pharma, respectively partnered with Merck & Co. and GSK, delivered…
In the past two weeks, CARsgen Therapeutics won the world's first regulatory approval for a solid tumor CAR-T, a…
